• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    1/26/24 4:25:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    SC 13G/A 1 lilly240086_sc13ga.htm SC 13G/A

     

         
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     
         
     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 39)

     

     

     
      Eli Lilly and Company  
     

     

    (Name of Issuer)

    Common Stock, Without Par Value

     
     

     

    (Title of Class of Securities)

    532457-10-8

     
     

     

    (CUSIP Number)

    December 31, 2023

     
     

     

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

     

    o Rule 13d-1(c)

     

    ü Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

    1 of 5

     

     

    CUSIP No. 532457-10-8 13G  

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

    LILLY ENDOWMENT INC.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

    (b) ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    INDIANA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

    5

    SOLE VOTING POWER

    99,768,810

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    99,768,810

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    99,768,810

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    Not applicable

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.51%

    12

    TYPE OF REPORTING PERSON

    CO

           

    FOOTNOTES:

    The percent of class represented is based on 949,307,237 shares of common stock outstanding as of October 30, 2023, as reported on the Issuer’s Form 10Q for the period ended September 30, 2023.

    2 of 5

     

    Item 1.

    (a)Name of Issuer

    Eli Lilly and Company

     

    (b)Address of Issuer's Principal Executive Offices

    Lilly Corporate Center, Indianapolis, Indiana 46285

     

     

    Item 2.

    (a)Name of Person Filing

    This statement is filed by Lilly Endowment Inc., a not for profit corporation organized under the laws of the State of Indiana. Lilly Endowment Inc is an organization described in Section 50l(c)(3) of the Internal Revenue Code of 1986 and is a private foundation under Section 509(a) of the Code.

     

    (b)Address of Principal Business Office or, if none, Residence

    The address of the principal business office of Lilly Endowment Inc. is 2801 No 11th Meridian Street, Indianapolis, Indiana 46208.

     

     

    (c)Citizenship

    Indiana

     

    (d)Title of Class of Securities

    Common Stock, Without Par Value

     

    (e)CUSIP Number

    532457-10-8

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)o Broker or dealer registered under section 15 of the Act.
         
     (b)o Bank as defined in section 3(a)(6) of the Act.
         
     (c)o Insurance company as defined in section 3(a)(19) of the Act.
         
     (d)o Investment company registered under section 8 of the Investment Company Act of 1940.
         
     (e)o An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).
         
     (f)o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).
         
     (g)o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
         
     (h)o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
     (i)o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
    Investment Company Act of 1940.
         
     (k)o A group, in accordance with§ 240. I 3d-l(b)(l )(ii)(K). If filing as a non-U.S. institution in accordance with§ 240.13d-l(b)(I)(ii)(J), please specify the type of institution.

    3 of 5

     

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned

           99,768,810

     

    (b)Percent of Class

            10.51%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote
         
        99,768,810
         
       (ii) Shared power to vote or to direct the vote
         
        0
         
       (iii)Sole power to dispose or to direct the disposition of
         
        99,768,810
         
       (iv) Shared power to dispose or to direct the disposition of
         
        0

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.Notice of Dissolution of Group

    Not Applicable

     

    Item 10.Certification

     

    Not Applicable

    4 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: January 19, 2024 Lilly Endowment Inc.
       
      By: /s/ Diane M. Stenson
      Name: Diane M. Stenson
      Title: Vice President & Treasurer

     

     

    Footnotes: Item 4: This information is provided as of December 31, 2023.
       
      Item 4(a): None of such shares are deemed to be beneficially owned by reason of the possession of Lilly Endowment Inc. of a right to acquire such shares.
       
      Item 4(b): The percent of class represented is based on 949,307,237 shares of common stock outstanding as of October 30, 2023 as reported on the Issuer’s Form 10Q for the period ended September 30, 2023.

    5 of 5 

    Get the next $LLY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    11/10/2025$1104.00Market Perform → Outperform
    Leerink Partners
    10/20/2025$840.00 → $930.00Outperform
    BMO Capital Markets
    10/14/2025Hold → Buy
    Erste Group
    9/17/2025$830.00Buy → Hold
    Berenberg
    8/27/2025$700.00Reduce → Hold
    HSBC Securities
    8/18/2025$700.00Outperform → Neutral
    Daiwa Securities
    8/7/2025$715.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Eli Lilly with a new price target

    Scotiabank initiated coverage of Eli Lilly with a rating of Sector Outperform and set a new price target of $1,165.00

    11/13/25 9:14:47 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Eli Lilly from Market Perform to Outperform and set a new price target of $1,104.00

    11/10/25 8:34:23 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Eli Lilly with a new price target

    BMO Capital Markets reiterated coverage of Eli Lilly with a rating of Outperform and set a new price target of $930.00 from $840.00 previously

    10/20/25 8:56:47 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly to participate in Citi's 2025 Global Healthcare Conference

    INDIANAPOLIS, Nov. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m., Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days. About LillyLilly is a medicine company turning science into healing to make life better for people around the world.

    11/18/25 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

    Halda Therapeutics acquired by Johnson & Johnson for $3.05 billion – the largest acquisition ever across any therapeutic area for a Phase 1 company Scorpion Therapeutics acquired by Eli Lilly for Up to $2.5 billion - one of the highest-value strategic transactions announced in early 2025 Vigil Neuroscience acquired by Sanofi for a $470 million upfront plus contingent value right (CVR) - advancing a potential breakthrough in Alzheimer's disease Capstan Therapeutics acquired by AbbVie for a record-breaking $2.1 billion – the highest ever for a company with only healthy-volunteer data Halda and Capstan each broke industry records in 2025, marking a historic year for Vida and under

    11/17/25 6:07:00 PM ET
    $ABBV
    $JNJ
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'

    New innovative campaign weaves science and storytelling to help reframe obesity as a chronic disease INDIANAPOLIS, Nov. 10, 2025 /PRNewswire/ -- For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and advocate, he's spent years helping people express their individuality through what they wear. But he's also seen first-hand the stigma carried by people living with obesity, amplified by society's misunderstanding of the science behind the chronic disease and the persistent belief that obesity is simply a failure of willpower. Experience the full interactive Multichannel News Release here: https://www.multivu.com/eli-lilly/9360951-en-t

    11/10/25 9:12:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    SEC Filings

    View All

    SEC Form 144 filed by Eli Lilly and Company

    144 - ELI LILLY & Co (0000059478) (Subject)

    11/12/25 3:15:03 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Eli Lilly and Company

    10-Q - ELI LILLY & Co (0000059478) (Filer)

    10/30/25 11:15:28 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ELI LILLY & Co (0000059478) (Filer)

    10/30/25 7:03:41 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lilly Endowment Inc sold $176,098,702 worth of shares (167,526 units at $1,051.17), decreasing direct ownership by 0.18% to 92,644,452 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    11/20/25 4:00:06 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lilly Endowment Inc sold $62,306,969 worth of shares (60,213 units at $1,034.78), decreasing direct ownership by 0.06% to 92,811,978 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    11/19/25 4:00:06 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Johnson Kimberly H was granted 215 shares, increasing direct ownership by 7% to 3,265 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    11/18/25 4:39:57 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Financials

    Live finance-specific insights

    View All

    Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance

    Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound.Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a non-GAAP basis. Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. Pipeline progress included positive results in four Phase 3 trials of orforglipron, across type 2 diabetes and obesity, with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity. Regulatory progre

    10/30/25 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly declares fourth-quarter 2025 dividend

    INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new d

    10/27/25 2:00:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for third-quarter 2025 financial results announcement

    INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into heal

    10/16/25 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    2/13/24 5:04:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    1/26/24 4:25:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Anne White to Retire as Executive Vice President and President, Lilly Neuroscience

    INDIANAPOLIS, Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor."Anne's career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases affecting patients globally," said David A. Ricks, Lilly's chair and CEO. "As leader of Lilly Neuroscience, Anne led the global launch of our first ever Alzh

    8/20/25 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care